171 related articles for article (PubMed ID: 30459283)
1. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
3. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
[TBL] [Abstract][Full Text] [Related]
4. Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.
Chen K; Lv F; Xu G; Zhang M; Wu Y; Wu Z
Oncotarget; 2016 Nov; 7(46):75968-75980. PubMed ID: 27732954
[TBL] [Abstract][Full Text] [Related]
5. BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.
Uçkun E; Siaw JT; Guan J; Anthonydhason V; Fuchs J; Wolfstetter G; Hallberg B; Palmer RH
J Mol Biol; 2021 Sep; 433(19):167158. PubMed ID: 34273398
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
Li T; Deng Y; Shi Y; Tian R; Chen Y; Zou L; Kazi JU; Rönnstrand L; Feng B; Chan SO; Chan WY; Sun J; Zhao H
Oncogene; 2018 Nov; 37(47):6180-6194. PubMed ID: 30013190
[TBL] [Abstract][Full Text] [Related]
7. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
8. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
9. Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors.
Li J; Wang Y; Li L; Or PM; Wai Wong C; Liu T; Ho WLH; Chan AM
Mol Oncol; 2021 Aug; 15(8):2011-2025. PubMed ID: 33932101
[TBL] [Abstract][Full Text] [Related]
10. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
12. Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.
Takagi D; Tatsumi Y; Yokochi T; Takatori A; Ohira M; Kamijo T; Kondo S; Fujii Y; Nakagawara A
Cancer Sci; 2013 May; 104(5):563-72. PubMed ID: 23360421
[TBL] [Abstract][Full Text] [Related]
13. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
Del Grosso F; De Mariano M; Passoni L; Luksch R; Tonini GP; Longo L
BMC Cancer; 2011 Dec; 11():525. PubMed ID: 22192458
[TBL] [Abstract][Full Text] [Related]
15. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.
Zhang G; Scarborough H; Kim J; Rozhok AI; Chen YA; Zhang X; Song L; Bai Y; Fang B; Liu RZ; Koomen J; Tan AC; Degregori J; Haura EB
Sci Signal; 2016 Oct; 9(450):rs12. PubMed ID: 27811184
[TBL] [Abstract][Full Text] [Related]
16. Insulin receptor substrate 2 and FoxO3a signalling are involved in E-cadherin expression and transforming growth factor-β1-induced repression in kidney epithelial cells.
Carew RM; Browne MB; Hickey FB; Brazil DP
FEBS J; 2011 Sep; 278(18):3370-80. PubMed ID: 21777391
[TBL] [Abstract][Full Text] [Related]
17. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
[TBL] [Abstract][Full Text] [Related]
18. High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.
Alshareef A; Gupta N; Zhang HF; Wu C; Haque M; Lai R
Sci Rep; 2017 Dec; 7(1):16863. PubMed ID: 29203817
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
20. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
